Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich’s Genous(TM) Stent in Diabetic Patients

March 23, 2011

HONG KONG, March 23, 2011 /PRNewswire/ — OrbusNeich today announced that 12-month outcomes data from a subset analysis of the global e-HEALING registry were published online ahead of print in the Journal of Interventional Cardiology and demonstrated the effectiveness and safety of the company’s Genous Stent in diabetic patients, with low definite and probable stent thrombosis (ST) comparable to non-diabetics.

The study investigated the 1,236 diabetic patients from the e-HEALING registry, including 273 insulin requiring diabetics (IRD) and 963 non-insulin requiring diabetics (NIRD), and compared this cohort to the non-diabetic study participants.

The investigators found a target vessel failure (TVF) rate of 10 percent in diabetics, compared to 7.9 percent in non-diabetics. The TVF rates were 13.4 percent and 9 percent in IRD and NIRD, respectively. The higher TVF rates were driven mainly by a higher mortality hazard in both diabetic subgroups when compared to non-diabetics. The target lesion revascularization (TLR) rates were comparable in diabetics and non-diabetics, with 6.4 percent in diabetics versus 5.4 percent in non-diabetics. Definite or probable ST occurred in 1.1 percent of both diabetics and non-diabetics.

“Diabetics treated with percutaneous coronary intervention remain a high-risk subgroup,” said Peter Damman, M.D., of the Academic Medical Center in Amsterdam and lead author of the paper. “These data show that Genous provides an effective alternative for managing thrombotic risk in this challenging group of patients.”

The primary outcome for the e-HEALING registry was TVF at 12-month follow-up. TVF was defined as the composite of cardiac death or myocardial infarction (MI), unless unequivocally attributed to a non-target vessel, and target vessel revascularization (TVR).

The median age of the diabetic cohort was 64 years, 73 percent were male, and the mean body mass index (BMI) was 28.3. In diabetics, an average of 1.4 lesions per patient was treated, with an average of 1.1 Genous Stents per lesion. Off all lesions, 10 percent were bifurcation lesions, 97 percent were de novo lesions, and 48 percent were type B2/C lesions.

Michael Kutryk, M.D., Ph.D., clinician scientist and an interventional cardiologist at St. Michael’s Hospital, as well as an assistant professor at the University of Toronto, added, “Patients with cardiovascular risk factors, including diabetes, have a reduced number of circulating endothelial progenitor cells (EPCs) that is due to either a direct influence on the mobilization and half-life of the EPCs or to a depletion of these cells caused by continuous endothelial damage or dysfunction. Capturing circulating EPCs with the unique Genous technology promotes and restores the natural healing process that is impaired in diabetics.”

About Genous

Genous is OrbusNeich’s patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC. Development stage products include the Combo(TM) Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com. Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich.

SOURCE OrbusNeich


Source: newswire